Nonclinical Safety & Pharmacokinetics, Director Onsite

Nonclinical Safety & Pharmacokinetics, Director, Contract, Onsite

Contract Director, Develop ability and Early CMC Development (1‑Year contract, Full‑Time, On‑Site)

Location:

Pine Tree Therapeutics, Cambridge, MA

Job Type: Contract (12 months, potential to convert to FTE)

Start Date:

Immediately

About Pine Tree Therapeutics:

Pine Tree Therapeutics is an innovative biotech company pioneering multispecific degrader antibodies to revolutionize cancer treatment. Our proprietary platform is designed to target and degrade membrane‑bound and extracellular proteins, offering a new approach to overcoming drug resistance in oncology. We are advancing a robust preclinical pipeline and actively preparing for translational and early clinical development.

This role provides scientific and strategic leadership in early CMC development. The Director will oversee development of late‑stage drug candidates with analytical and develop ability screening and cell line development. Working on‑site, the Director will play a critical role in ensuring efficient candidate selection and optimizing therapeutic candidates for manufacturability, scalability, and regulatory compliance.

We are seeking an experienced and motivated Director of Develop ability and Early CMC Development to join our team on a full‑time, one‑year contract basis. This position will play a critical role in the early‑stage assessment of monoclonal and multispecific antibodies coming out of the Discovery pipeline and advancing them to cell line development.

• Supervise and mentor direct reports.
• Manage interactions within cross‑functional teams.

• Establish fit‑for‑purpose analytical/purification methods to support multivalent therapeutic antibodies, ADC or protein/antibody fusion lead screening and further development in leveraging both proprietary (in‑house) technologies and external (CRO/partner) capabilities to accelerate lead identification and candidate advancement.
• Execute purification and analytical utilizing modern equipment to support the programs at early discovery or late‑stage development including UPLC‑MS, LC‑MS, RP‑HPLC, HIC‑HPLC, CEX‑HPLC and different affinity chromatography et al.
• Provide strategic input into candidate selection based on robust develop ability assessment outcomes, balancing scientific rigor with resource efficiency, tailored to a small biotech environment.
• Collaborate cross‑functionally with Discovery, Molecular Biology, and Translational Research teams to ensure seamless transition from research to clinical development.
• Lead and oversee the early‑stage CMC development strategy and execution for monoclonal and multivalent antibody candidates to the IND submission.
• Design, implement, and manage comprehensive develop ability and pre‑formulation screening, evaluating parameters such as cell productivity, aggregation, glycosylation patterns, post‑translational modifications, solubility, stability.
• Establish and optimize workflows, ensuring alignment of internal processes with industry best practices.
• Manage relations with external CDMOs for CMC activities including process transfers, problem resolution, timeline management, and budget oversight.
• Author key sections of IND applications related to CMC.
• Communicate effectively with senior management and external partners regarding CMC strategies, progress, and risk management.
• Foster a culture of innovation, teamwork, and continuous performance improvement.

• PhD or advanced degree in Biochemistry, Chemistry, Biotechnology, (bio) chemical Engineering, or a related scientific discipline.
• 10+ years of experience in advancing biological molecules from late research to CMC development, specifically focused on monoclonal and multi‑specific antibody therapeutics.
• Demonstrated hands‑on expertise in designing, optimizing, and validating analytical and purification techniques to support the screening and development of multivalent therapeutic antibodies. Skilled in leveraging both proprietary (in‑house) technologies and external (CRO/partner) capabilities to accelerate lead identification and candidate advancement.
• Proven track record…